Scientific Publications

Hypoxia Activated Prodrugs

  • Efficacy of the Hypoxia-Activated Prodrug TH-302 in a Preclinical Model of Prostate Cancer Metastasis, C.Hart et al., American Association for Cancer Research (AACR) Centennial Meeting, August 2008.
  • Anti-cancer activity of Hypoxia-Activated Prodrug, TH-302 in H460 non-small cell lung carcinoma metastatic, J.Sun et al., American Association for Cancer Research (AACR) Centennial Meeting, August 2008.
  • Targeting Tumor Hypoxia with TH-302 and Complementary Chemotherapy, J.Curd et al., American Association for Cancer Research (AACR) Conference on Translational Medicine, July 2008.
  • Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs, J. Duan et al., Journal of Medicinal Chemistry, 51: 2412-2420, 2008.
  • In vitro activity profile of the novel hypoxia-activated cytotoxic prodrug, TH-302, C.Hart et al., American Association for Cancer Research (AACR) Annual Meeting, April 2008.
  • Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the hypoxically activated prodrug, TH-302, in mice, rats, dogs and monkeys, D.Jung et al., American Association for Cancer Research (AACR) Annual Meeting, April 2008.
  • Anti-cancer activity of TH-1011, a novel Hypoxia-activated prodrug, is related to tumor vessel disruption, J.Sun et al., American Association for Cancer Research (AACR) Annual Meeting, April 2008.
  • Discovery of TH-302: an achiral hypoxia-activated cytotoxic prodrug, C. Hart et al., American Society of Clinical Oncology (ASCO) Annual Meeting, June 2007.
  • in vivo anti-cancer activity of a hypoxia activated prodrug, TH-302, J. Wang et al., American Association for Cancer Research (AACR) Annual Meeting, April 2007.
  • A cell-based screening platform for hypoxia-activated prodrugs, J.W. Evans et al., American Association for Cancer Research (AACR) Annual Meeting, April 2006.

Glufosfamide

  • A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma, E.G. Chiorean et al., Cancer Chemother Pharmacol (2008) 61:1019-1026
  • Preliminary Efficacy and Safety Results of Glufosfamide (GLU) in Relapsed Soft Tissue Sarcoma: Results of a Phase 2 Trial, G.D’Amato et al., American Society of Clinical Oncology (ASCO) Annual Meeting, June 2008.
  • Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: results of a phase III trial (TH-CR-302), V.K. Langmuir et al., European Cancer Conference (ECCO) Annual Meeting, September 2007.
  • Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a phase 2 trial (TH-CR-301), E.G. Chiorean et al., European Cancer Conference (ECCO) Annual Meeting, September 2007.
  • Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group, E. Briasoulis et al., European Journal of Cancer, 39: 2334-2340, 2003.
  • Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group, E. Briasoulis et al., Journal of Clinical Oncology 18: 3535-3544, 2000.

2-Deoxyglucose (2-DG)

  • Glycolytic inhibition with 2-Deoxy-glucose in patients with lung and head and neck cancers, L.E. Raez et al., ASCO 2006.

Research

  • Antiproliferative activity of 3-bromopyruvate is not due to selective inhibition of glycolysis, F.Meng et al., American Association for Cancer Research (AACR) Annual Meeting, April 2008.
  • A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity, F. Meng et al., Cancer Chemotherapy and Pharmacology, 61: 953-963, 2008.
  • Potent anti-tubulin tumor cell cytotoxins based on 3-aroyl indazoles, J. Duan et al., Journal of Medicinal Chemistry, 50: 1001-1006, 2007.
  • 3-aroyl indazoles: their synthesis and potential use for cancer treatment, J.Duan et al., American Association for Cancer Research (AACR) Annual Meeting, April 2007.
  • ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1α accumulation, F. Meng et al., Anti-Cancer Drugs, 18: 435-445, 2007.